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SUMMARY
Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by mutations of the survival of motor neuron 1 (SMN1) gene. In the
pathogenesis of SMA, pathological changes of the neuromuscular junction (NMJ) precede the motor neuronal loss. Therefore, it is
critical to evaluate the NMJ formed by SMA patients’ motor neurons (MNs), and to identify drugs that can restore the normal condition.
We generated NMJ-like structures using MNs derived from SMA patient-specific induced pluripotent stem cells (iPSCs), and found that
the clustering of the acetylcholine receptor (AChR) is significantly impaired. Valproic acid and antisense oligonucleotide treatment
ameliorated the AChR clustering defects, leading to an increase in the level of full-length SMN transcripts. Thus, the current in vitro
model of AChR clustering using SMA patient-derived iPSCs is useful to dissect the pathophysiological mechanisms underlying the
development of SMA, and to evaluate the efficacy of new therapeutic approaches.
INTRODUCTION
Proximal spinal muscular atrophy (SMA) is an autosomal
recessive neuromuscular disorder caused by the homozy-
gous deletion or mutation of the survival of motor neuron 1
(SMN1) gene, resulting in a deficiency of the ubiquitously
expressed SMN protein. Patients suffer from progressive
muscular weakness, which eventually results in respiratory
failure in severe case. Since there are no effective treatment
options, SMA remains the most frequent genetic cause of
infant mortality (Burghes and Beattie, 2009; Lefebvre
et al., 1995). SMN2, a unique gene in humans, is an almost
identical copy gene of SMN1, but has a constitutive C to T
transition in its exon 7. This transition affects the splicing
of SMN2 mRNA, thereby resulting in the predominant
production of a shorter unstable isoform termed SMN-D7
(Monani et al., 1999). Although SMN2 is unable to
compensate for the homozygous loss of SMN1 because
of the lower amount of full-length SMN transcripts
(SMN-FL), the copy number of SMN2 affects the severity
of SMA (McAndrew et al., 1997).
Based on clinical examinations and the pathological
analyses of end-stage specimens, SMA historically has
been described as a lower motor neuron (MN) disease char-
acterized by the degeneration of the anterior horn cells of
the spinal cord, which subsequently leads to skeletal mus-
cle atrophy and weakness (Dubowitz, 2009). However,
recent studies in SMA animal models have shown that
the earliest detectable pathological change is observed at
the neuromuscular junctions (NMJs), including neurofila-
ment (NF) accumulation at the endplate on postnatal day
1 (Ling et al., 2012). Subsequently, a central synaptic
defect is observed on day 4, motor neuronal loss manifests
around day 9, and almost all mice die by day 15 (Sleigh
et al., 2011). Therefore, impairment of the NMJ structure
appears to be one of the most important phenotypes, and
the development of agents that target the NMJ pathology
may represent an attractive approach for therapy. Indeed,
an aberrant ultrastructure of NMJs also has been reported
in a human prenatal specimen obtained from a fetus with
type I SMA (Martı´nez-Herna´ndez et al., 2013).
Despite recent advances in our understanding of the
disease, the detailed mechanism(s) involved in the NMJ
formation and maturation, which occur during both the
prenatal and early postnatal periods, have not been fully
described (Wu et al., 2012).With a few exceptions, the ana-
lyses of the pathological roles of SMNhave been conducted
mainly using animal models, because there are difficulties
associated with obtaining human specimens from either
biopsy or post-mortem samples. Although there are several
available transgenic mouse models of SMA, inter-species
differences between mice and humans, such as the
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existence of SMN2 in humans, hamper the translation of
the findings in mouse studies to human clinical trials (Har-
ahap et al., 2012; Martı´nez-Herna´ndez et al., 2009; Park
et al., 2010). Furthermore, there are difficulties related to
evaluating the pathological roles of neurons and myocytes
separately. To establish a platform to elucidate the pathol-
ogy of the NMJ in SMA patients, we herein evaluated the
ability of MNs from SMA patient-derived induced pluripo-
tent stemcells (iPSCs) (Takahashi et al., 2007) to formNMJs.
RESULTS
Generation and Characterization of iPSCs from Type 1
SMA Patients
Fibroblasts from two independent type 1 SMA patients
(Coriell IDs GM00232 and GM03813, referred to as P1
and P2) were reprogrammed by episomal vectors (Okita
et al., 2011). Both SMA-iPSC clones used in this study (P1
and P2) showed a characteristic human embryonic stem
cell (ESC)-like morphology, and expressed pluripotent
markers compared to control ESC (KhES1) and iPSCs
(201B7 and 409B2, referred to as C1 and C2) (Figures S1A
and S1B). The RNA microarray analysis confirmed that
the global gene expression pattern (Figures S1C and S1D)
and levels of pluripotent stemcell-related genes (Figure S1E)
in the P1 and P2 iPSCs were similar to that observed in the
control iPSCs. The P1 and P2 iPSCs also exhibited demethy-
lation of NANOG and OCT3/4 loci (Figure S1F) and main-
tained a normal karyotype (Figure S1G). Pluripotency of P1
and P2 iPSC lines were confirmed by teratoma formation
assay (Figure S1H). The expression of introduced trans-
genes was rarely detected (Figure S1I). The genetic identity
of the iPSC clones was proven by a short tandem repeat
analysis (data not shown). SMA-iPSCs were confirmed
to carry homozygosis deletions of exons 7 and 8 of the
SMN1 gene (Figure 1A; van der Steege et al., 1995), and their
SMN protein level was also significantly lower than that in
control iPSCs, including C1 and C2 (Figures 1B and 1C).
MN Differentiation of SMA-iPSCs
Wenextdirected theSMA- andcontrol iPSCs todifferentiate
into MNs using a previously reported cortical neuron (Mor-
izane et al., 2011) and spinal MN differentiation protocol,
with some modifications (Egawa et al., 2012). The iPSC-
derived neurons expressed neuronal markers (Figure S2A)
and MN-specific markers (Figure 1D). The expression of
the introduced transgene OCT3/4 detected in the P1-iPSCs
was completely silenced after 40 days ofMN differentiation
(Figure S2B). Although a significant decline in MNs over
time has been reported as a hallmark of SMA patient iPSC-
derived MNs (Chang et al., 2011; Corti et al., 2012; Ebert
et al., 2009), the two independent SMA-iPSC lines produced
and maintained a similar number of HB9-positive MNs
compared to control iPSCs after 40 and 50 days of differen-
tiation (Figure 1E). Therefore, in our MN differentiation
system, the SMA-iPSC lines were competent in generating
matureMNs andpresentedno evidence of cell-autonomous
MN loss by 50 days of differentiation.
Figure 1. Differentiation of iPSCs into Spinal MNs
(A) The PCR restriction fragment-length polymorphism (RFLP)
analysis using a bioanalyzer confirmed that the SMA-iPSCs main-
tained exon 7 and 8 deletions in the SMN1 gene.
(B) Western blot analysis of SMN proteins.
(C) Quantification of the SMN protein expression relative to that of
b-actin (eight control PSC clones and two SMA-iPSC clones) (n = 3,
Wilcoxon rank-sum test).
(D) Immunostaining of SMA-iPSC-derived MNs. HB9, red; and ChAT,
green on day 60.
(E) The quantitative immunocytochemical analysis for HB9-posi-
tive iPSC-derived MNs (means ± SEM, n = 3). See also Figure S1.
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Formation of NMJ-like Structure with SMA-iPSCs
We next tried to develop an in vitro NMJ formation model
using the human iPSC-derived MNs. We co-cultured con-
trol MNs with differentiated murine C2C12 cell lines and
found that aBTX-positive AChRs were clustered at the
site of SV2-positive neuronal endplates (Figure 2A). To
exclude the presence of unexpected artifacts of aBTX
staining under these conditions, we co-stained samples
Figure 2. The Pre- and Post-synaptic
Morphological Defects in Type 1 SMA
(A–D) Representative confocal micrographs
showing the immunocytochemically labeled
NMJ-LSs of iPSC-derived neurons and C2C12
myotubes. (A and B) Representative images
of AChR clusters formed by C1 MNs. (C) AChR
clusters stained with MHC. (D) NMJ-LSs of
patient (P1)- and control (C1)-derived MNs
on day 60.
(E) Quantitative immunocytochemical ana-
lysis of the a-BTX-positive area (means ±
SEM, n = 3, Wilcoxon rank-sum test).
(F) Abnormal NF accumulation (yellow
arrows) and poor terminal arborization of
MNs in the SMA NMJ-LSs. See also Figure S2.
Stem Cell Reports j Vol. 4 j 561–568 j April 14, 2015 j ª2015 The Authors 563
with aBTX and anti-AChR antibodies and confirmed that
the regions of both positive staining merged completely
(Figure 2B). In addition, the AChR clusters were localized
on myosin heavy chain (MHC)-positive multinuclear
myotubes (Figure 2C).
We next evaluated the AChR clustering on myotubes
co-cultured with SMA-iPSC-derived MNs and found
it remarkably impaired (Figure 2D). We evaluated the
area of aBTX to assess the ability of MNs to form and
maintain the NMJ-like structures (NMJ-LSs). We evalu-
ated the AChR clustering at several time points to
determine whether MN maturation affects the pheno-
type of the NMJ-LSs. The SMA-iPSC-derived MNs induced
far less AChR clustering in myotubes than control
iPSC-derived MNs did at 40, 50, or 60 days of differenti-
ation (Figures 2E and S2C). AChR clustering was
rarely observed for either the SMA- or control iPSC-
derived MNs at time points earlier than day 30 (data
not shown). We also evaluated the average size of
each AChR cluster (Figure S2D) and number of AChR
clusters (Figure S2E). Consequently, the AChR clusters
formed with SMA-iPSC-derived MNs were smaller and
fewer in number than those formed with controls. To
evaluate whether co-culturing with MNs affects the
maturation status of C2C12, we compared the expression
levels of embryonic (Myh3) and perinatal (Myh8) sub-
types of MHCs in skeletal muscle with or without
co-culturing (Stern-Straeter et al., 2011; Figure S2F).
However, the ratio of expression of these genes was not
different, indicating a lack of difference in the matura-
tion of C2C12.
Although motor neuronal loss was not observed in our
MN differentiation system without co-culture, there re-
mains a possibility that the NMJ defects in SMA patient-
derived MNs are due to MN death occurring under the
co-culture conditions. To exclude the possibility, we per-
formed TUNEL staining of the MNs (Figures S2G and
S2H). The number of TUNEL-positive apoptotic MNs
did not increase during co-culturing, which confirms
that synapse loss indeed occurs in surviving MNs. The
accumulation of NF proteins and poor arborization in
distal axons and motor nerve terminals are considered
to be specific features of SMA model mice, although
their significance in the pathogenesis of human SMA is
unknown (Cifuentes-Diaz et al., 2002; Kariya et al.,
2008; Kong et al., 2009). These findings were observed
in SMA-iPSC-derived MNs (Figure 2F), which indicates
the functional deficit of the motor endplate in SMA.
Taken together, the SMA-iPSC-derived MNs had impaired
AChR clustering on myotubes in the absence of MN loss,
indicating that there was functional impairment of MNs
in terms of their forming or allowing for the maturation
of NMJs.
The SMA Phenotype in NMJ-LS Was Rescued by
Valproic Acid and Phosphorodiamidate Morpholino
Oligonucleotides
Since the loss of NMJ formation is regarded to be an
important hallmark preceding the motor neuronal loss,
compounds that ameliorate the NMJ pathology may serve
as promising therapeutic drug candidates. To evaluate
whether the NMJ-LSs formation system used in our ex-
periments can serve as a prototype for evaluating drug
candidates, we assessed whether the SMN-inducing drug,
valproic acid (VPA), could increase the AChR clustering
in our co-culture system. VPA is known to increase the
functional SMN protein by activating various promoters,
including that of SMN2, and by correcting the abnormal
splicing of SMN2 exon 7, mainly through the upregu-
lation of splicing factors (Harahap et al., 2012). Co-
culturing myotubes and SMA-iPSC-derived MNs treated
with VPA significantly increased the AChR clustering
(Figures 3A–3C and S3A), while the clustering was not
induced when monocultured myotubes were treated
with VPA (data not shown). NF accumulation was not
rescued by VPA treatment (Figure 3A). We confirmed
that VPA treatment increased both the SMN-D7 and
SMN-FL mRNA levels in the SMA-iPSC-derived MNs
(Figure 3D).
We next performed an RNA sequencing (RNA-seq)
analysis to evaluate the effects of VPA on the expression
profiles of the MNs, and we found 227 genes that were
upregulated more than 2-fold in the VPA-treated MNs,
whereas 51 genes were downregulated (Figure S3B;
Tables S1 and S2). The expression levels of splicing factors
known to be affected by VPA treatment (Brichta et al.,
2003; Harahap et al., 2012) were slightly upregulated as
reported, in both the control and patient-derived MNs
(Figure S3C).
To further explore the validity of NMJ-LSs, we next
evaluated the effects of splicing modification on SMN2.
Recently, the application of antisense oligonucleotides
to promote SMN2 exon 7 retention has been proposed
as an alternative therapeutic approach for SMA (Mitrpant
et al., 2013). For this purpose, we introduced phosphoro-
diamidate morpholino oligonucleotides (PMOs) targeting
the intronic silencing motif in SMN2 intron 7. Conse-
quently, the SMN-specific PMO treatment dramatically
improved AChR clustering with the patient-derived
MNs (Figures 4A, 4B, and S3D). The PMO treatment
also recovered the expression of SMN-FL (Figure 4C)
and improved, at least partially, the abnormal NF
accumulation (Figure 4A). We consider that these data
indicate the potential therapeutic advantages of PMO
for SMA patients. Overall, the NMJ-LS morphology could
be useful for evaluating new therapeutic approaches
for SMA.
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DISCUSSION
Previous studies regarding the phenotype of MNs differen-
tiated from SMA-iPSCs have focused mainly on the cell
autonomous defects, such as shortened neurite extension,
and the reduced size of the cell body; but, their significance
in relation to the in vivo phenotype remains unclear
(Chang et al., 2011; Ebert et al., 2009). Although motor
neuronal loss during culture also has been reported, this
is not observed in vivo until the end stage of the disease.
We did not observe any progressive motor neuronal loss
during culture, even during the longer time period, which
is contrary to the previous reports (Chang et al., 2011; Corti
et al., 2012; Ebert et al., 2009; Sareen et al., 2012). The
precise reason for this difference is unknown, but a variety
of methodological differences during culture, such as dif-
ference in the timing of the analysis, the protocol of MN
differentiation, and the methods used for the evaluation,
could all have contributed to this phenotypic variation.
Although Corti et al. briefly reported the detection of
NMJ defects after co-culturing human myoblasts and
SMA-iPSC-derived MNs in a recent report (Corti et al.,
2012), MN loss was observed without co-culturing the cells
with myotubes in their SMA model, leaving the possibility
Figure 4. PMO Treatment Rescues the
NMJ Pathology in SMA Patient-Derived
Cell Cultures
(A) Representative images of NMJ-LSs
formed with or without PMOs. Yellow arrows
indicate abnormal NF accumulation.
(B) Quantitative immunocytochemical
analysis of the a-BTX area after PMO treat-
ment (means ± SEM, n = 3, Student’s t test).
(C) The mRNA levels of SMN-FL and SMN-D7
with PMO treatment (means ± SEM, n = 3,
Student’s t test). See also Figure S3.
Figure 3. VPA Treatment Rescues the
NMJ Pathology in SMA Patient-Derived
Cell Cultures
(A) Representative images of NMJ-LSs
formed with or without VPA. Yellow arrows
indicate abnormal NF accumulation.
(B and C) Quantitative immunocytochem-
ical analysis of the a-BTX area after VPA
treatment (1 mM) (means ± SEM, n = 3,
Student’s t test).
(D) The mRNA levels of SMN-FL and SMN-D7
in SMA-iPSC MNs (means ± SEM, n = 3,
Student’s t test). See also Figure S3 and
Tables S1 and S2.
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that preceding motor neuronal death may have led to the
defect in forming the NMJ. In contrast, the patient-derived
iPSCs used in our study yielded a similar ratio of HB9+MNs
compared to the two control lines. Moreover, we observed
a significant reduction in AChR clustering, with no signif-
icant increases in the number of TUNEL-positiveMNs, dur-
ing co-culturing.
Sincewe focused on the pathology of NMJ, we performed
a detailed examination of our NMJ-LS. To evaluate whether
the developmental status of the MNs affects the NMJ
pathology, we evaluated AChR clustering at three different
time points and obtained consistent data. In addition to
impaired AChR clustering, we detected abnormal pre-
synaptic NF accumulation at the endplate in the SMA-
iPSC-derived neurons, which also indicates that synaptic
breakdown precedes motor neuronal death in our model.
These data support a hypothesis that MNs derived from
patient iPSCs are a major contributing factor to the patho-
genesis in the NMJ due to SMA. Based on these obser-
vations, we considered that the morphological defect of
NMJ-LS in our culture was due to functional impairments
of the MNs in target pathfinding and/or in inducing or
maintaining AChR clustering, rather than due to motor
neuronal loss. Considering that the formation andmainte-
nance of NMJs has been indicated to precede the occur-
rence of MN death even in humans, as mentioned above,
the vulnerability of MNs in SMA patients seems to be due
not only to the autonomous cell susceptibility to various
stresses, but also as a consequence of theNMJ defect, which
causes the impairment of neurotrophic factors and sub-
sequent death of MNs (Fidzianska and Rafalowska, 2002;
Fischer et al., 2004).
In summary, we demonstrated that the early SMApheno-
type in NMJ could be recapitulated with MN differentiated
from SMA-iPSCs. Since the available outcome measures to
assess the drug efficacy in SMA are limited, our findings
that the NMJ is a vulnerable target amenable to rescue by
VPA and PMOs seems to indicate that this system will be
useful for future evaluations of novel therapeutic candi-
dates. Further experiments with patient-derived iPSCs on
the neurodevelopmental aspects of the neuromuscular
system, including specific molecular and cellular functions
of SMN in both muscle and MN, will provide new insights
into the pathophysiology of SMA. We believe that this
approach will also help deepen our understanding of the
pathogenesis of the muscle and MN interactions on the
formation of the NMJ.
EXPERIMENTAL PROCEDURES
Study Approval
Use of human ESCs was approved by the Ministry of Education,
Culture, Sports, Science and Technology of Japan (MEXT). The
study plan for recombinant DNA research has been approved by
the recombinant DNA experiments safety committee of Kyoto
University. An experimental protocol was approved by the Animal
Research Committee of CiRA, Kyoto University.
MN Differentiation and Co-culture with C2C12
The iPSCs were dissociated into single cells and quickly re-aggre-
gated in DFK 5% medium (DMEM/F12 medium supplemented
with KSR, NEAA, 2-mercaptoethanol, L-Glutamate, SB431542,
dorsomorphin, and Y27632) (9,000 cells/150 ml/well) using
96-well low cell-adhesion plates (Lipidure-coat U96w from Nunc)
(Eiraku et al., 2008; Morizane et al., 2011). From day 8, the cell
aggregates were treated with Sonic hedgehog (100 ng/ml) and
retinoic acid (1 mM) for 1 week (Wada et al., 2009). On day 20,
the cell aggregates were plated onto poly-l-lysin/laminin-coated
culture dishes in neuronal medium (neurobasal medium [Gibco]
supplemented with the neurotrophic factors GDNF, BDNF, and
NT3 [10 ng/ml, R&D Systems]). The medium was changed every
3 to 4 days thereafter.
For the co-culture with neuronal cells, the fusion of C2C12
myoblasts was induced by switching to the differentiation
medium (DMEM supplemented with horse serum). On day 4,
the MNs that had differentiated from the iPSCs (differentiation
days 34–54) were harvested and plated on the induced myotubes,
and the medium was changed to neuronal medium. Thereafter,
the cultures were fed every 2 days by changing half of the
medium.
VPA Treatment
Co-cultured samples were treated with or without 1 mM VPA by
changing half of the medium every 2 days. After 6 days of drug
treatment, the area of NF and aBTX immunostaining was detected
by immunocytochemistry and was analyzed by the IN Cell
Analyzer 2000 software program.
PMO Treatment
Designed PMOs SMN2E7D(-10-29) for suppressing splice silencing
motifs in intron 7 of SMN2 (Mitrpant et al., 2013) and its negative
control were purchased from Gene Tools. SMN- or Ctrl-PMO
(10 mM in medium) were introduced with the Endo-Porter (Gene
Tools) on day 1 of co-culturing, and the cells were subsequently
cultured for 3 days.
Statistics
Statistic functions in Microsoft Excel 2013 were used for statisti-
cal analyses. Statistical significance was determined using Stu-
dent’s t test and Wilcoxon rank-sum test, p < 0.05 was considered
significant, and n represents the number of independent
experiments.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, three figures, and three tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2015.02.010.
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